In­flu­en­tial proxy firms kick back at ac­tivists’ de­mands for Brent Saun­ders to give up his chair­man’s ti­tle at Al­ler­gan

Af­ter sav­ing Bris­tol-My­ers Squibb last week from the em­bar­rass­ing dis­as­ter of see­ing its $74 bil­lion Cel­gene buy­out go south, the proxy ad­vi­so­ry firms In­sti­tu­tion­al Share­hold­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER